Miltenyi Biotec announces the worldwide first and exclusive release of the Anti-GLAST (ACSA-1) MicroBead Kit. Isolation of viable GLAST-expressing astrocytes is now possible within one hour using the first commercially available antibody against an extracellular surface epitope of GLAST. Magnetic cell separation with MACS(R) Technology is the method of choice for the specific isolation of viable cells. A prerequisite for specific cell isolation is the availability of antibodies directed against a specific cell surface antigen. Suitable antibodies against extracellular markers on the astrocyte cell surface were not available until recently, and astrocytes had to be isolated by time-consuming methods, such as generation of astrocyte cultures, which even differ considerably from astrocytes in vivo, or by transgenic approaches.
The new anti-GLAST (ACSA-1) antibody (astrocyte cell surface antigen 1; ACSA-1) recognizes an extracellular epitope of the astrocyte-specific glutamate transporter GLAST (EAAT1), and it shows specific and sensitive labeling of GLAST-positive cells in flow cytometry, immunohistochemistry, and immunocytochemistry.
"The Anti-GLAST (ACSA-1) MicroBead Kit provides the first tool for the straightforward isolation of astrocytes from dissociated brain tissue, and enables the separation of astrocytes based on their expression of GLAST," says Dr. Melanie Jungblut, the responsible R&D Project Manager. "The kit allows for the direct isolation of viable primary astrocytes within one hour, and achieves high purity by minimizing contamination by other cells."
The Anti-GLAST (ACSA-1) MicroBead Kit is exclusively available from Miltenyi Biotec.
First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution